Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
Jazyk angličtina Země Spojené státy americké Médium electronic
Typ dokumentu klinické zkoušky, fáze III, dopisy, multicentrická studie, práce podpořená grantem
PubMed
34671024
PubMed Central
PMC8528829
DOI
10.1038/s41408-021-00562-9
PII: 10.1038/s41408-021-00562-9
Knihovny.cz E-zdroje
- MeSH
- dexamethason aplikace a dávkování škodlivé účinky MeSH
- humanizované monoklonální protilátky aplikace a dávkování škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom * farmakoterapie imunologie MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování škodlivé účinky MeSH
- senioři MeSH
- thalidomid aplikace a dávkování škodlivé účinky analogy a deriváty MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- dexamethason MeSH
- humanizované monoklonální protilátky MeSH
- isatuximab MeSH Prohlížeč
- pomalidomide MeSH Prohlížeč
- thalidomid MeSH
Ankara University School of Medicine Department of Hematology Ankara Turkey
Department of Hematology Hospital De Haut Leveque University Hospital Pessac France
Hematology Service University Hospital La Princesa Madrid Spain
Sanofi Oncology Cambridge MA USA
Sanofi R and D Vitry sur seine France
University of Melbourne Epworth Healthcare Melbourne Australia
Zobrazit více v PubMed
Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025–31. doi: 10.1182/blood-2010-09-307645. PubMed DOI
Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775–82. doi: 10.1200/JCO.2008.17.9721. PubMed DOI
van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–406. doi: 10.3324/haematol.11534. PubMed DOI
Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28:2612–24. doi: 10.1200/JCO.2009.25.4250. PubMed DOI
Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35. doi: 10.1001/jamaoncol.2016.3160. PubMed DOI PMC
Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–68. doi: 10.1182/blood-2014-11-568907. PubMed DOI PMC
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–548. doi: 10.1016/S1470-2045(14)70442-5. PubMed DOI
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–107. doi: 10.1016/S0140-6736(19)32556-5. PubMed DOI
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl J Med. 2003;348:2609–17. doi: 10.1056/NEJMoa030288. PubMed DOI
Muccio S, Tavernier A, Rouchon MC, Alain R, Dai S, Boutet V, et al. M-protein semi quantification in MM serum patients based on immuno-capture and liquid chromatography coupled to high resolution mass spectrometry. Clin Lymphoma Myeloma Leukemai. 2019;19:E149–50. doi: 10.1016/j.clml.2019.09.249. DOI
Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transpl. 2016;51:1565–8. doi: 10.1038/bmt.2016.222. PubMed DOI PMC
Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009;114:2617–8. doi: 10.1182/blood-2009-01-198788. PubMed DOI PMC
McCudden C, Axel AE, Slaets D, Dejoie T, Clemens PL, Frans S, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54:1095–104. doi: 10.1515/cclm-2015-1031. PubMed DOI
Tang F, Malek E, Math S, Schmotzer CL, Beck RC. Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab. Am J Clin Pathol. 2018;150:121–9. doi: 10.1093/ajcp/aqy037. PubMed DOI
Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109. doi: 10.1038/s41408-018-0141-0. PubMed DOI PMC
